Intracervical vasopressin to help hysteroscopic removal of retained pregnancy tissue.
Official title: Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception
Run by Prisma Health-Upstate · NCT07102615 · Data updated 2026-11-12
This test checks whether injecting vasopressin into the cervix during hysteroscopic removal helps women 18–51 have complete removal of retained pregnancy tissue.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 51 Years |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | Prisma Health-Upstate Academic / other |
| Locations | 1 site (Greenville, South Carolina) |
| Status | Recruiting |
| Started | October 30, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT07102615 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–51 undergoing hysteroscopic surgical management for retained products of conception after miscarriage, abortion, or delivery who are hemodynamically stable and able to consent.
✕Probably not a fit
Patients with active heavy bleeding, hemodynamic instability, known allergy to vasopressin, suspected intrauterine arteriovenous malformation, or inability to consent are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This double-blind randomized controlled trial compares intracervical vasopressin to saline placebo given during hysteroscopic removal of retained products of conception in women aged 18–51. Participants are randomized to receive either vasopressin or a placebo injection into the cervix at the time of the procedure. The primary outcome is surgical completion, defined as completing hysteroscopic removal without converting to suction because of bleeding or poor visualization. Secondary outcomes include intraoperative bleeding, operative time, and fluid deficit measurements.
Why it matters
Potential benefit: If successful, this could increase complete hysteroscopic removals of RPOC with less bleeding and fewer conversions to suction.
How similar studies have gone: Vasopressin has been used in other gynecologic surgeries to reduce bleeding, but its intracervical use specifically for improving hysteroscopic removal of RPOC is not well-established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women * Aged 18-51 * Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion Exclusion Criteria: * Hemodynamic instability * Active hemorrhage- soaking pad/hour * Allergy to vasopressin * Concern for intrauterine arteriovenous malformation * Inability to consent
Where it's running
-
The OB/GYN Center
Greenville, South Carolina, United States Recruiting
Study contacts
- Study coordinator: Patti Parker, BSN
- Email: patti.parker@prismahealth.org
- Phone: 864-455-1510
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Drug-assisted expectant care versus surgery for retained products of conception
This project tests whether trying drug-assisted expectant management and waiting for the right time for surgery in people with retained products of conception reduces intrauterine scarring and better preserves fertility compared with immediate curettage.
-
Operative hysteroscopy in the operating room versus the outpatient clinic
This will test whether operative hysteroscopy done in an outpatient clinic works as well as when it's done in the operating room for women treated for fibroids, polyps, or retained products of conception.
-
Evaluating conservative management for retained products of conception and enhanced myometrial vascularity
This study is testing if gentle treatments for people with leftover pregnancy tissue after a miscarriage can help them recover naturally over two menstrual cycles.
-
Using hyaluronic acid gel to prevent adhesions after surgery for retained pregnancy tissue
This study is testing if a special gel can help prevent complications like infertility after surgery for leftover pregnancy tissue.
-
Hysteroscopy for treating retained products of conception after miscarriage
This study tests whether a procedure called hysteroscopy helps women who had a miscarriage and still have some pregnancy tissue to get pregnant again faster compared to just waiting it out.
-
Misoprostol versus watchful waiting for retained tissue after first-trimester medical abortion
This project will test whether taking misoprostol or simply watching and waiting works better to clear retained tissue after a first‑trimester medical abortion in women aged 18–45 with ultrasound evidence of retained products.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.